Abstract
Migraine is a mysterious disorder characterized by pulsating head ache, which is actually characterized to one side and comes in attacks which will be lasting for about 3-48 hours and can be associated with nausea,vomiting,sensitivity to sound,flashes of light,vertigoand diarrhoea [1]. Most of the drugs which are in current use for actue migraine like triptans, treats the disorder symptomatically. A novel group of drugs has been in research for the migraine which treats the disorder pathologically. Calcitonin gene – related peptide (CGRP) has a major role in the pathophysiology of the disorder and hence CGRP receptor antagonist, known as Gepants are in the research process [2]. Gepants are being studied for the efficacy of treating acute migraine [2]. This article will be a review article about the drug – Ubrogepant, which is approved for treatment of migraine with acute attacks in adults [3].
Highlights
Migraine is a mysterious disorder characterized by pulsating head ache, which is characterized to one side and comes in attacks which will be lasting for about 3-48 hours and can be associated with nausea,vomiting,sensitivity to sound,flashes of light,vertigoand diarrhoea [1]
*Corresponding author: E-mail: adrilthecute1@gmail.com; Padmaja and Mohan; JPRI, 33(56A): 79-81, 2021; Article no.JPRI.76639 enzymes [5], a newer Calcitonin gene – related peptide (CGRP) – Ubrogepant was approved by the FDA on 23rd December 2019 by the ALLERGAN COMPANY, is a promising and more potent drug with reduced risk of hepatotoxicity [3]
Patients diagnosed with Migraine and either with or without aura was recruited in the trial after the completion of Phase II trials
Summary
Migraine is a mysterious disorder characterized by pulsating head ache, which is characterized to one side and comes in attacks which will be lasting for about 3-48 hours and can be associated with nausea,vomiting,sensitivity to sound,flashes of light,vertigoand diarrhoea [1]. Though previous CGRP antagonist can be associated with nausea, vomiting, drugs like Telcagepant produced increased liver *Corresponding author: E-mail: adrilthecute1@gmail.com; Padmaja and Mohan; JPRI, 33(56A): 79-81, 2021; Article no.JPRI.76639 enzymes [5], a newer CGRP – Ubrogepant was approved by the FDA on 23rd December 2019 by the ALLERGAN COMPANY, is a promising and more potent drug with reduced risk of hepatotoxicity [3].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
